Sulfadiazine partially protects the rat temporal cortex from amyloid beta peptide (25-35)-induced alterations of the somatostatinergic system

Neuroendocrinology

Volumn 89, Issue 4, 2009, Pages 400-410

  Burgos Ramos, E ^a,b   Puebla Jimenez L ^b   Hernandez Pinto A ^b   Arilla Ferreiro, E ^b  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Alzheimer's disease; Amyloid beta peptide (25 35); Somatostatin; Sulfadiazine

Indexed keywords

ADENYLATE CYCLASE; AMYLOID BETA PROTEIN[25-35]; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 2; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SULFADIAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CANNULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; LATERAL BRAIN VENTRICLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RIGHT HEMISPHERE; TEMPORAL CORTEX;

AMYLOID BETA-PROTEIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SULFADIAZINE; TEMPORAL LOBE;

EID: 67650214954     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000194657     Document Type: Article

References (65)

1. Domagk G: Ein Beitrag zur Chemoterapie der bakteriellen Infektionen. Dtsch Med Wochenschr 1935;61:250-256.
2. Hackman CH: Beobachtungen über die Be-einflussbarkeit von Alterserscheinungen bei Versuchstieren. Münch Med Wochenschr 1958;100:1814-1817.
3. Becker A: Beobachtungen über Debenal in der Geriatrie. Münch Med Wochenschr 1959;73:1737-1741.
4. Ravina A, Hackman CH: Some considerations on the pathogenesis and treatment of aging. Presse Méd 1967;75: 885-886.
5. Sparey T, Beher D, Best J, Castro JL, Clarke E, Hannam J, Harrison T, Lewis H, Madin A, Shearman M, Sohal B, Tsou N, Welch C, Wrigley J: Cyclic sulfamide γ-secretase inhibitors. Bioorg Med Chem Lett 2005;15: 4212-4216.
6. Sambamurti K, Greig NH, Lahiri DK: Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002;1:1-31.
7. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
8. Shaw D, Best J, Dinnell K: 3,4-Fused cyclohexyl sulfones as γ-secretase inhibitors. Bioorg Med Chem Lett 2006;16:3073-3077.
9. Katzman R, Saitoh T: Advances in Alzheimer's disease. FASEB J 1991;5:278-286.
10. Haass C, Selkoe DJ: Soluble protein in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 1993;8:101-112.
11. Mc Geer EG, McGeer PL: Inflammatory processes in Alzheimeŕs disease. Prog Neur Psychopharmacol Biol Psy 2003;7:741-749.
12. Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron D, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995;374:647-650.
13. Masters CL, Beyreuther K: The neuropathology of Alzheimer's disease;in Beal MF, Lang AE, Ludolph AC (eds): Neurodegenerative Diseases: Neurobiology Pathogenesis and Therapeutics. Cambridge, Cambridge University Press, 2005, pp 433-440.
14. Pierotti CJ, Harmar A, Simpson J, Yates C: High molecular weight forms of somato-statin are reduced in Alzheimer's disease and Down's syndrome. Neurosci Lett 1985;63: 141-14 6 .
15. Garret B, Finsen B, Wree A: Parcellation of cortical areas by in situ hybridation for somatostatin mRNA in the adult rat: frontal, parietal, occipital and temporal regions. Anat Embr yol (Berl) 1994;19 0: 389-398.
16. Pérez J, Rigo M, Kaupmann K, Bruns C, Yasuda K, Bell GI, Lubbert H, Hoyer D: Localization of somatostatin (SR IF) SSTR1, SSTR 2 and SSTR3 receptor mRNA in rat brain by in situ hybridation. Naunyn Schmiedeberg's Arch Pharmacol 1994;349:145-160.
17. Feindt J, Becker I, Blömer U, Hugo HH, Mehdom HH, Krisch B, Mentlein R: Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 1995;65:1997-2005.
18. Bell GI, Reisine T: Molecular biology of somatostatin receptors. Trends Neurosci 1993; 16:34-38.
19. Schettini G, Florio T, Meucci O, Landolfi E, Grimaldi M, Ventra C, Marino A: Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Res 1989;492: 65-71.
20. Cacabelos R, Niigawa H, Rodríguez-Arnao MD, Gomez-Pan A, Nishimura T: Influence of somatostatin and growth hormone-releasing factor on behaviour. Horm Res 1988; 29:129-132.
21. Dournaud P, Jazat-Pondessous F, Slama A, Lamour Y, Epelbaum J: Correlations between water maze and cortical somatostatin mRNA and high-affinity binding sites during ageing in rats. Eur J Pharmacol 1996;8: 476-485.
22. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature 1980;288:279-280.
23. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martin JB: Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 1985;229:289-291.
24. 1 receptor subtype in frontal and temporal cortices in Alzheimer's disease. Brain Res 1992;573:299-304.
25. Cowburn RF, Fowler CJ, Garlind A, Alafuzoff I, Nilsson L, Winbland B, Bergström L: Somatostatin receptors and the modulation of adenylate cyclase activity in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991; 54:748-749.
26. Aguado-Llera D, Arilla-Ferreiro E, Campos-Barros A, Puebla-Jiménez L, Barrios V: Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of P-amyloid-treated rats. J Neurochem 2005;92:607-615.
27. Ravina A: Une thérapeutique nouvelle de la vieillesse et des états de sénescence. Presse Méd 1965;73:1737-1741.
28. Hussain Z, Carlson ML, Craig ID, Lamnigan R: Efficacy of tetroxoprim/sulphadiazine in the treatment of Pneumocystis carinii pneumonitis in rats. J Antimicrob Chemother 1985;15:575-578.
29. Nitta A, Itoh A, Hasegawa T, Nabeshima T: β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994; 170:63-66.
30. 3H]dopa in various regions of the brain. J Neurochem 1966;13:655-669.
31. 131I-labelled human growth hormone of high specific radioactivity. J Biochem 1963;89:114-123.
32. Reubi JC, Perrin MH, Rivier JE, Vale W: High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci 1981;28: 2191-2198.
33. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin-phenol reagent. J Biol Chem 1951;193:265-275.
34. Czernik AJ, Petrack V: Somatostatin receptor binding in rat cerebral cortex: characterization using a nonreducible somatostatin analog. J Biol Chem 1983;28:5525-5530.
35. Munson PJ, Rodbard D: Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-239.
36. Aguilera G, Parker DS, Catt KJ: Characterization of somatostatin receptor in the rat adrenal glomerulosa zone. Endocrinology 1982;111:1376-1384.
37. Patel YC, Reichlin S: Somatostatin in hypothalamus extrahypothalamic brain and peripheral tissues of the rat. Endocrinology 1978;102:523-530.
38. Houslay MD, Metcalfe JC, Warren GB, Hesketh TR, Smith GA: The glucagon receptor of rat liver plasma membrane can couple to adenylate cyclase without activating it. Biochem Biophys Acta 1976;436:489-494.
39. Gilman AG: A protein binding assay for adenosine 3prime;:5′-cyclic monophosphate. Proc Natl Acad Sci USA 1970;67:305-312.
40. Aguado-Llera D, Martín-Martínez M, García- López MT, Arilla-Ferreiro E, Barrios V: Gly-Pro-Glu protects β-amyloid-induced somatostatin depletion in the rat cortex. Neuroreport 2004;15:1979-1982.
41. Burgos Ramos E, Hervás-Aguilar A, Puebla Jiménez L, Boyano Adánez MC, Arilla Ferreiro E: Chronic but not acute intracerebroventricular administration of amyloid beta peptide (25-35) decreases somatostatin content, adenylate cyclase activity, somatostat-in-induced inhibition of adenylate cyclase activity and adenylate cyclase I levels in the rat hippocampus. J Neurosci Res 2007;85: 433-442.
42. Yankner BA, Duffy LK, Kirshnet DA: Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990;250:279-282.
43. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield A: Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J Am Chem Soc 2001;123:5625-5631.
44. 26]Aβ25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 2002;70:474-483.
45. García N, Santafé MM, Tomás M, Lanuza MA, Tomás J: Short-term effects of beta-amyloid 25-35 peptide aggregates on transmitter release in neuromuscular synapses. J Neuropathol Exp Neurol 2008;67:250-259.
46. Hervás-Aguilar A, Puebla-Jiménez L, Burgos-Ramos E, Aguado-Llera D, Arilla-Ferreiro E: Effects of single and continuous administration of amyloid β-peptide (25-35) on adenylyl cyclase activity and the somatostatinergic system in the rat frontal and parietal cortex. Neuroscience 2005;135:181-190.
47. Maurice T, Sockhart BP, Su TP, Privat A: Reversion of beta-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agoinsts. Brain Res 1996;731:249-253.
48. Rall DP: Experimental studies of the blood-brain barrier. Cancer Res 1965;65:1572-1577.
49. Johnstone M, Gearing AJ, Miller KM: A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999;93:182-193.
50. Singh VK: Studies of neuroinmune markers in Alzheimer's disease. Mol Neurobiol 1994; 9:73-81.
51. Toro VC, Tehranian R, Zetterstrom M, Eriksson G, Langel U, Bartfai T, Iverfeld K: Increased gene expression of interleukin-1 alpha and interleukin 6 in rat primary glial cells induced by beta-amyloid fragment. J Mol Neurosci 2001;17:341-350.
52. Araujo DM, Lapchak PA, Collier B, Quirion R: Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic systems. Brain Res 1989;498:257-266.
53. Hanisch UK, Seto D, Quirion R: Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 1993;13:3368-3374.
54. Lapchak PA, Araujo DM: Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. Neuroreport 1993;4:303-306.
55. Dickson DW, Lee SC, Mattiage LA, Yen SH, Brosnan C: Microglia and cytokines in neurological disease with special reference to AIDS and Alzheimer's disease. Glia 1993;7: 75-83.
56. Kittur SD, Kittur DS, Soncrant TT, et al: Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol 1990;28:168-173.
57. Karanth S, Agula MC, McCann SM: The influence of interleukin-2 on the release of so-matostatin and growth hormone-releasing hormone by mediobasal hypothalamus. Neuroendocrinology 1993;58:185-190.
58. McCann SM, Kimura M, Karanth S, Yu WH, Mastronardi CA, Rettori V: The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Ann NY Acad Sci 2000;917:4-18.
59. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, Yu C, Arkin MR, Raimundo BC: Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc 2003;125:3714-3715.
60. Waal ND, Yang W, Oslob JD, Arkin MR, Hyde J, Lu W, McDowell RS, Yu CH, Rai-mundo BC: Identification of nonpeptidic small-molecule inhibitors of interleukin-2. Bioorg Med Chem Lett 2005;15:983-987.
61. O'Neill C, Wiehager B, Fowler CJ, Ravid R, Winbland B, Cowburn RF: Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain. Brain Res 1994;636:193-201.
62. Kato K, Kurobe N, Suzuki F, Marishita R, Asano T, Imagaki T: Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease. J Mol Neurosci 1991;3:95-99.
63. 2A in rat brain using a specific anti-peptide antibody. J Neurosci 1996;16: 4468-4478.
64. Dutar P, Vaillerd C, Viollet C, Billard JM, Potier B, Carlo AS, Ungerer A, Epelbaum J: Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice. Neuroscience 2002;112: 455-466.
65. Yamaguchi Y, Kawashima S: Effects of amyloid-β-(25-35) on passive avoidance, radialarm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 2001;412:265-272.